Media Centre
Latest press releases
-
Lynparza approved in the EU for 1st-line maintenance treatment of BRCA-mutated advanced ovarian cancer
-
Calquence significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia
-
Lokelma demonstrated efficacy in treating hyperkalaemia in patients with end-stage renal disease on haemodialysis
-
Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia
-
Lynparza achieved a 72% objective response rate in patients with relapsed, germline BRCA-mutated advanced ovarian cancer
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
Contact us
Gonzalo Viña
Head of Global Media Relations
Rob Skelding
Director Global Media Relations
Matthew Kent
Director Global Media Relations
Rebecca Einhorn
Director Global Media Relations
Jennifer Hursit
Manager Global Media Relations
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
Lotta Sjösten
Manager Media Relations, Sweden
US Media Team
